SKN | Wells Fargo Raises AbbVie Price Target to $340 as Expanding Drug Pipeline Strengthens Long-Term Growth Outlook

Key Points

• Wells Fargo increased its AbbVie (NYSE: ABBV) price target from $300 to $340 while maintaining an Overweight rating, citing stronger pipeline prospects and improving commercial opportunities.
• Wells Fargo now projects approximately $107 billion in AbbVie sales by 2035, compared with its previous estimate of $95 billion, reflecting additional contributions from pipeline assets and higher product forecasts.
• Third-quarter 2026 adjusted earnings reached $3.82 per share, while revenue totaled $17.4 billion, supported by continued demand for key immunology treatments, including Skyrizi.

Wells Fargo Sees Greater Long-Term Value in AbbVie’s Pharmaceutical Pipeline

Wells Fargo has raised its price target on AbbVie to $340 from $300, maintaining an Overweight rating as the investment bank identifies improving commercial prospects and additional long-term value across the pharmaceutical company’s development pipeline.

The revised target reflects a stronger assessment of AbbVie’s growth potential, supported by stable access to its immunology and inflammation treatments, expanding opportunities for existing medicines, and encouraging demand for newer products.

AbbVie shares were recently trading at $294.89, close to their 52-week high of $298.74, following a 44.63% increase over the preceding six months.

Despite the strong share price performance, Wells Fargo believes the company’s longer-term revenue potential supports a higher valuation. However, other valuation assessments, including InvestingPro’s Fair Value analysis, suggest that the stock may already be trading above estimated intrinsic value.

For institutional investors, the central consideration is whether AbbVie’s expanding pipeline can sustain earnings growth sufficiently to justify its current market valuation.

Immunology Portfolio Provides Support for Existing Revenue Growth

Wells Fargo’s revised outlook incorporates several developments across AbbVie’s established pharmaceutical portfolio.

The firm highlighted stable market access for the company’s immunology and inflammation treatments, alongside the potential for Skyrizi’s subcutaneous induction offering to create additional commercial opportunities.

Rinvoq’s label expansion also supports the existing business by potentially broadening its addressable patient population and reinforcing its competitive position within the immunology market.

Meanwhile, demand for Juvmo has provided another positive contribution to Wells Fargo’s revenue expectations.

These developments are important because the strength of AbbVie’s existing commercial portfolio provides a foundation for financing research, development, and future product launches.

For investors, the combination of established pharmaceutical franchises and expanding treatment opportunities offers a framework for assessing the company’s ability to maintain revenue growth over an extended period.

Pipeline Additions Increase AbbVie’s Long-Term Valuation Potential

The principal driver behind Wells Fargo’s higher price target is the inclusion of additional pharmaceutical candidates in its valuation model.

The investment bank incorporated ABBV-466, ABBV-969, and bretisilocin into its pipeline assessment, alongside higher estimates for Juvmo and etentamig.

These additions increase the projected contribution of AbbVie’s research and development activities to its long-term commercial outlook.

Wells Fargo now estimates that AbbVie could generate approximately $107 billion in sales by 2035, compared with its previous projection of approximately $95 billion.

This represents a substantial upward revision and reflects the firm’s expectations that additional pipeline products could expand the company’s future revenue base.

However, pharmaceutical pipeline valuations remain dependent on clinical development outcomes, regulatory approvals, commercial adoption, and competitive conditions. The projected revenue contribution should therefore be viewed as an investment scenario rather than guaranteed future performance.

Third-Quarter Results Reinforce AbbVie’s Commercial Performance

AbbVie’s third-quarter 2026 financial results provide additional support for the company’s operating outlook.

The pharmaceutical group reported adjusted earnings of $3.82 per share, exceeding the analyst consensus estimate of $3.74. Revenue reached $17.4 billion, slightly above expectations of $17.36 billion.

The company also raised its full-year financial outlook and increased its quarterly dividend, reflecting confidence in its operating performance and shareholder distribution capacity.

Skyrizi remained an important contributor, generating approximately $5.78 billion in quarterly sales and marginally exceeding the consensus estimate of $5.74 billion.

The results attracted further analyst attention. UBS subsequently raised its price target on AbbVie to $295 from $275 while maintaining a Neutral rating.

The differing assessments from Wells Fargo and UBS illustrate how analysts can interpret the same operating performance differently when evaluating pipeline opportunities, future earnings, and valuation assumptions.

Closing Insights: Pipeline Execution Will Determine AbbVie’s Next Growth Phase

Wells Fargo’s revised price target highlights the growing importance of AbbVie’s development pipeline in shaping its long-term investment outlook.

The company’s established immunology portfolio, expanding treatment opportunities, and stronger-than-expected quarterly performance provide support for its current commercial position. Additional pipeline contributions could further strengthen revenue prospects if clinical and regulatory milestones are achieved.

For high-net-worth investors and institutional portfolios, AbbVie represents an opportunity to examine the relationship between pharmaceutical innovation, recurring commercial revenues, and long-term equity valuations.

However, the recent share price appreciation and differing analyst valuation assessments reinforce the importance of distinguishing between business quality and investment entry price.

Investors should monitor clinical trial developments, regulatory decisions, product adoption, patent exposure, research and development expenditure, and the sustainability of dividend distributions.

Ultimately, AbbVie’s ability to translate its expanding pipeline into commercially successful treatments will determine whether its revised long-term revenue expectations can be achieved. The company’s strategic value lies not only in its current pharmaceutical portfolio but also in its capacity to replenish and expand that portfolio through sustained innovation.

For a confidential discussion regarding retail banking strategy, insurance distribution models, customer loyalty ecosystems, digital financial services, or cross-border financial innovation opportunities, contact our senior advisory team.